ClinicalTrials.gg
RecruitingNCT06927570Updated Jan 16, 2026

A Study of HS-20122 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-20122 in Advanced Solid Tumors, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1,050
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Advanced Solid Tumors
  • HS-20122
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged ≥ 18 years.
  • Subjects with or cytologically confirmed locally advanced or Solid Tumors
  • Standard treatment is invalid, unavailable or intolerable.
  • At least 1 target lesion according to 1.1.
  • PS score: 0-1.
  • Estimated > 12 weeks.
  • Men or women should be using adequate measures throughout the study.
  • Women must have the evidence of non-.
  • Signed and dated Form.

Exclusion criteria

Exclusion Criteria:

  • Any unresolved toxicities from prior therapy greater than Grade 2 according to (CTCAE) 5.0 with the exception of alopecia or neurotoxicity
  • History of other primary .
  • Inadequate bone marrow reserve or organ dysfunction.
  • Evidence of cardiovascular risk.
  • Subjects with severe or poorly controlled diabetes.
  • Subjects with severe or poorly controlled hypertension.
  • Subjects with bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose.
  • Subjects with severe arteriovenous thrombotic events within 3 months.
  • Subjects with severe infection within 4 weeks prior to the first dose.
  • Subjects who have received therapy for more than 30 days .
  • Presence of known active infectious diseases.
  • Presence of clinically significant gastrointestinal dysfunction.
  • Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis ≥ Grade B.
  • Moderate to severe pulmonary diseases.
  • Prior history of significant neurological or mental disorders.
  • Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  • to any ingredient of HS-20122.
  • Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  • Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity
  • History of other primary malignancies.
  • Inadequate bone marrow reserve or organ dysfunction.
  • Evidence of cardiovascular risk.
  • Subjects with severe or poorly controlled diabetes.
  • Subjects with severe or poorly controlled hypertension.
  • Subjects with clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose.
  • Subjects with severe arteriovenous thrombotic events within 3 months.
  • Subjects with severe infection within 4 weeks prior to the first dose.
  • Subjects who have received steroid therapy for more than 30 days .
  • Presence of known active infectious diseases.
  • Presence of clinically significant gastrointestinal dysfunction.
  • Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis ≥ Child-Pugh Grade B.
  • Moderate to severe pulmonary diseases.
  • Prior history of significant neurological or mental disorders.
  • Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  • Hypersensitivity to any ingredient of HS-20122.
  • Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  • Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,050 participants (estimated)

Study arms

  • Experimental
    HS-20122

    All subjects will receive HS-20122 in a continuous regimen in dose escalation stage or dose expansion stage

    Drug: HS-20122

Interventions

  • DrugHS-20122

    Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

06

What researchers measure

Primary outcomes

  1. The maximum tolerated dose (MTD) or the maximum applicable dose (MAD)

    To determine the MTD or MAD for further evaluation of intravenous administration of HS-20122 in subjects with advanced solid tumors

    Time frame: From time of first dose of HS-20122 to end of DLT period (approximately 21 days)

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.

    Time frame: From time of Informed Consent to 28 days post last dose of HS-20122

  2. Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

    Time frame: From time of first dose of HS-20122 to end of DLT period (approximately 21 days)

  3. Observed maximum drug concentration (Cmax) of HS-20122 (including antibody-drug conjugates, total antibody, and payload)

    The Cmax is the maximum observed drug concentration of HS-20122

    Time frame: From the date of first dose until 30 days after the final dose

  4. Time to reach maximum observed drug concentration (Tmax) of HS-20122 (including antibody-drug conjugates, total antibody, and payload)

    The Tmax is defined as time to reach maximum observed drug concentration of HS-20122.

    Time frame: From the date of first dose until 30 days after the final dose.

  5. Area under the curve from time Zero to end of dosing interval (AUC0-t) of HS-20122 (including antibody-drug conjugates, total antibody, and payload)

    The AUC0-t is defined as the area under the drug concentration-time curve during a dose interval time period(t)

    Time frame: From the date of first dose to Cycle 4(each cycle is 28 days) pre-dose.

  6. Area under the curve from time Zero to end of dosing interval (AUC0-∞) of HS-20122 (including antibody-drug conjugates, total antibody, and payload)

    The AUC0-∞ is defined as the area under the drug concentration-time curve from time 0 to infinity

    Time frame: From the date of first dose to Cycle 4(each cycle is 28 days) pre-dose

  7. Incidence of anti-HS-20122 antibody (ADA)

    ADA incidence was defined as the percentage of participants whose ADA status were identified as positive.

    Time frame: From the date of first dose until 30 days after the final dose.

  8. Objective response rate (ORR)

    ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigators based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jan 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 15, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06927570
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Apr 15, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jan 16, 2026

Study contacts

Ketao Chen
Contact
chenkt@hspharm.com
18795500836

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion